Trial Profile
A Multicenter, Multinational, Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Revusiran in Patients with Transthyretin-mediated Familial Amyloidotic Cardiomyopathy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2020
Price :
$35
*
At a glance
- Drugs Revusiran (Primary)
- Indications Cardiomyopathies
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 27 Jul 2020 The trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 08 Feb 2017 Status changed from recruiting to discontinued due to safety findings, according to an Alnylam Pharmaceuticals media release.
- 20 Oct 2016 New trial record